Rationale for and outline of the recommendations of the working group on hypercholesterolemia and other dyslipidemias: Interim report

Canadian Journal of Cardiology

Volumn 14, Issue SUPPL. A, 1998, Pages

  Frohlich, J ^a,b   Fodor, G ^b,b   McPherson, R ^b   Genest, J ^b   Langner, N ^b,b   Hammell D M S , N ^b   Klassen, J ^b   Yokoyama, S ^b   MacLean, D R ^b   McPherson, P R ^b   Tan, M H ^b   Watson, A ^b   McMillan, J S ^b   Carroll, K ^b   Dery V ^b   Ledoux, M ^b   Little, A ^b   Bear Rogers, J ^b   Philip Mickelson, W ^b   Horvaeth, J ^b   Petrasovits, A ^b   Lupien, P ^b   more..

^a ST PAUL S HOSPITAL   (Canada)

^b NONE

Author keywords

Dyslipidemia; Guidelines; Hypercholesterolemia; Lipid disorder management

Indexed keywords

ANTILIPEMIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ANAMNESIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; DRUG CHOICE; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; HUMAN; HYPERCHOLESTEROLEMIA; LIFESTYLE; LIPID BLOOD LEVEL; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; RISK ASSESSMENT; SECONDARY PREVENTION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 7144227301     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.111/J.0828-282X     Document Type: Conference Paper

References (11)

1. Canadian Consensus Conference on Cholesterol: final report. The Canadian Consensus Conference on the Prevention of Heart and Vascular Disease by Altering Serum Cholesterol and Lipoprotein Risk Factors. Can Med Assoc J 1988;139(11 Suppl):1-8.
2. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA 1993;269:3015-23.
3. Pyorala K, DeBacker G, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994;5:1300-31.
4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
5. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9.
6. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
7. Savoie I, Bassett K, Kazanjian A. Supporting clinical practice guidelines development: an appraisal of existing cholesterol testing guidelines. BCOHTA Report 1997:12D.
8. Hayward RS, Guyatt GH, Moore KA, McKibbon KA, Carter AO. Canadian physicians' attitudes about and preferences regarding clinical practice guidelines. Can Med Assoc J 1997;156:1715-23.
9. Grover SJ, Coupai L, Hu XP. Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work? JAMA 1995;274:801-6.
10. Gotto AM. Triglyceride: the forgotten risk factor. Circulation 1998;97:1027-8.
11. Jeppesen J, Hein HO, Suadicani P, et al. Triglyceride concentration and ischemic heart disease: an 8-year follow-up in the Copenhagen Male Study. Circulation 1998;97:1029-36.